Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

The company's forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain's second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca's sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his "more constructive thesis" for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon's Savvas Neophytou remains more wary, pointing out that Soriot's predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca's longer-term prospects. "In our view, management is stepping onto thin ice with this same sort of guidance," Neophytou said, pointing out the previous management's failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb's share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts' revenue forecasts significantly, suggesting that a more realistic "adjusted consensus" for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company's thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body's immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients' lives significantly and generate tens of billions of dollars in annual sales.
Drugmaker AstraZeneca forecasts faster return to growth.

Use of such pills, which include Sanofi SA's Ambien and other similar drugs, was significantly higher for those in their 50s as well as age 80 and older, according to the findings from the Centers for Disease Control and Prevention. Overall about 8.6 million people, or 4 percent of U.S. adults reported recently using sleep medication, CDC's National Center for Health Statistics said in a report. But data showed higher use among middle-aged adults ages 50 to 59 and the elderly. Six percent of those ages 50 to 59 said they had taken a prescription sleep pill in the last 30 days, and 7 percent of those age 80 and older reported such use. In between, the numbers dip slightly below 6 percent for those in their 60s and 70s. In comparison, just 2 percent of those aged 20-39 said they had recently taken a sleep aid. CDC researcher Yinong Chong said people in their 50s could have trouble sleeping because of work and family stress. "It gives the picture of a sandwiched group who has family, not only children but also probably elderly parents but still you're likely to be in the workforce, so you get squeezed at both ends in terms of family responsibility and job responsibility," she said. Sleep may improve when people retire before potential chronic health problems kick in and begin interfering with sleep, Chong said, adding more study is needed. The data also showed that 5 percent of women surveyed said they had recently taken a sleep aid compared to about 3 percent of male respondents, according to CDC's report. Chong said it was not clear why women were more likely to use the drugs. While previous data have tracked prescriptions dispensed for sleep aids, the CDC said its study is the first based on a survey of actual use of such drugs. Researchers for the Atlanta-based health agency's National Center for Health Statistics questioned a sampling of adults age 20 and older about whether they had used prescription sleep aids within the last 30 days and asked participants to show interviewers the prescription medication. "You get how many people are actually using them," Chong said in an interview, noting that prescription data could include multiple prescriptions for one patient or prescriptions that are never filled or even used. "This is actual use." Prescription sleep aids have become somewhat controversial because their effect can linger even after some patients wake up. The U.S. Food and Drug Administration has begun taking a closer look at sleep drugs, ordering lower-doses for Ambien and similar pills amid concerns that their active ingredient remained in patients' blood the following morning at levels high enough to make driving and other activities dangerous. And just last month, the FDA rejected an experimental sleep drug from Merck & Co Inc, saying the proposed doses were not safe but that a lower-dose version might be acceptable. Not surprisingly, respondents to CDC's study who said they slept five hours or less each night or those diagnosed with a sleep disorder were more likely to report using prescription aids. Additionally, more whites and people with higher levels of education also reported greater use, the agency said. Socioeconomic factors are likely behind those numbers, Chong said, since patients must be able to afford a doctor's care and the medication. According to prescription data from IMS Health, Ambien and other versions of the drug zolpidem was ranked 15th among the most dispensed medications in the United States.
Use of sleeping pills highest among older Americans: CDC.

Senators Richard Burr and Thom Tillis issued statements saying they will vote against Dourson to serve as head of EPA's Office of Chemical Safety and Pollution Prevention. Environmentalists and Senate Democrats have vehemently opposed Dourson, a toxicologist with close ties to the chemical industry. That means only one more Republican "no" vote would likely be needed to torpedo his nomination. Moderate GOP Sen. Susan Collins of Maine told reporters Thursday she is also leaning against supporting Dourson, but has not yet made a final decision. The White House and EPA did not respond to requests for comment Wednesday or Thursday. Despite the fact he hasn't yet been confirmed by the Senate, Dourson has already been working at the agency as a senior adviser to EPA Administrator Scott Pruitt. The agency's press office did not respond to emails seeking how much he is being paid. The Associated Press reported in September that Dourson has for years accepted payments for criticizing studies that raised concerns about the safety of his clients' products, according to a review of financial records and his published work. Past corporate clients of Dourson and of a research group he ran include Dow Chemical Co., Koch Industries Inc. and Chevron Corp. His research has also been underwritten by industry trade and lobbying groups representing the makers of plastics, pesticides, processed foods and cigarettes. Burr and Tillis, both of whom are considered reliably pro-business conservatives, cited Dourson's past work and worries among their home-state constituents about tainted drinking water in opposing his nomination. "Over the last several weeks, Senator Tillis has done his due diligence in reviewing Mr. Dourson's body of work," said a statement from Tillis' office. "Senator Tillis still has serious concerns about his record and cannot support his nomination." Marine veterans and their families blame decades-old contamination of wells at a North Carolina base with solvents and dry-cleaning chemicals for infant deaths and serious health problems that include cancer. More recently, concerns have been raised about undisclosed discharges of chemicals used to manufacture Teflon and GoreTex into the Cape Fear River, a source of municipal drinking water for Wilmington and other southeastern North Carolina communities. Dourson worked at the EPA for more than a decade, leaving in 1994 as the manager at a lab that assessed the health risks of exposure to chemicals. The following year, he founded Toxicology Excellence for Risk Assessment, a private toxicity evaluation nonprofit organization that tests chemicals and produces reports on which chemicals are hazardous in what quantities. Dourson's views toward industry are consistent with others Trump has selected as top federal regulators. Among them is Pruitt, who in March overruled the findings of his agency's own scientists to reverse an effort to ban chlorpyrifos, one of the nation's most widely used pesticides. Court records show Dourson and his work have often been called on when his corporate clients are seeking to fend off lawsuits. DuPont was accused of polluting a West Virginia town with Perfluorooctanoic acid, or PFOA, a chemical that the company's internal tests had long ago concluded was toxic. Corporate officials discussed hiring Dourson as part of a strategy to defend themselves. Dourson led a team that found in 2002 that PFOA levels up to 150 parts per billion were safe, a level higher than was found in testing of 188 private wells and springs. That was also well above the 1 part per billion that Dupont's own scientists had concluded could be considered safe years before. The EPA now says that only 70 parts per trillion of PFOA are acceptable or only 0.05 percent of what Dourson's team said was safe. DuPont and a former subsidiary, Chemours Co., later paid $761 million to settle 3,550 lawsuits stemming from its use of the chemical. Chemours is the company whose spills of a chemical called GenX, a replacement for PFOA, are now at issue in North Carolina's Cape Fear River. "I will not be supporting the nomination of Michael Dourson," said Burr, the state's senior senator. "With his record and our state's history of contamination at Camp Lejeune as well as the current GenX water issues in Wilmington, I am not confident he is the best choice for our country." The stand was quickly praised by environmental advocacy groups that rarely find common ground with the two Tarheel Republicans. "No one who has spent decades arguing on behalf of the chemical industry for weaker safety standards should be charged with reviewing chemicals for the EPA," said Scott Faber, a senior vice president for government affairs at the Environmental Working Group. "It would be like putting an arsonist in charge of the fire department." ___ Follow Associated Press environmental reporter Michael Biesecker at http://twitter.com/mbieseck
Trump EPA nominee opposed by GOP senators from NC.